CO2020002576A2 - Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica - Google Patents
Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológicaInfo
- Publication number
- CO2020002576A2 CO2020002576A2 CONC2020/0002576A CO2020002576A CO2020002576A2 CO 2020002576 A2 CO2020002576 A2 CO 2020002576A2 CO 2020002576 A CO2020002576 A CO 2020002576A CO 2020002576 A2 CO2020002576 A2 CO 2020002576A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- treatment
- compounds
- compositions
- neurological dysfunction
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title abstract 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020002576A2 true CO2020002576A2 (es) | 2020-04-01 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0002576A CO2020002576A2 (es) | 2017-08-16 | 2020-03-04 | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11427573B2 (enExample) |
| EP (1) | EP3668865A1 (enExample) |
| JP (1) | JP7253832B2 (enExample) |
| KR (1) | KR102687118B1 (enExample) |
| CN (1) | CN111225913B (enExample) |
| AU (1) | AU2018317403B2 (enExample) |
| BR (1) | BR112020003292A2 (enExample) |
| CA (1) | CA3072493A1 (enExample) |
| CL (1) | CL2020000360A1 (enExample) |
| CO (1) | CO2020002576A2 (enExample) |
| EA (1) | EA202090467A1 (enExample) |
| IL (1) | IL272575B2 (enExample) |
| PE (1) | PE20200756A1 (enExample) |
| SG (1) | SG11202001264UA (enExample) |
| UA (1) | UA128084C2 (enExample) |
| WO (1) | WO2019036534A1 (enExample) |
| ZA (1) | ZA202001321B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112020003292A2 (pt) | 2017-08-16 | 2020-08-18 | Vanderbilt University | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2024121367A1 (en) * | 2022-12-08 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Novel substituted pyrazine-carboxamide-imidazopyridine derivatives |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| SI2120932T1 (sl) | 2006-12-20 | 2014-09-30 | Nerviano Medical Sciences S.R.L. | Indazolni derivati kot kinazni inhibitorji za zdravljenje raka |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| SG173465A1 (en) | 2009-01-28 | 2011-09-29 | Univ Vanderbilt | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2456310A4 (en) | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| IN2012DN02580A (enExample) | 2009-09-04 | 2015-08-28 | Univ Vanderbilt | |
| BR112012009574A2 (pt) | 2009-10-22 | 2019-09-24 | Univ Vanderbilt | potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica |
| CN103079570A (zh) | 2009-11-06 | 2013-05-01 | 范德比尔特大学 | 芳基或者杂芳基砜类用作治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN102892288B (zh) | 2010-02-11 | 2016-02-24 | 范德比尔特大学 | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 |
| BR112012020271A2 (pt) | 2010-02-11 | 2017-08-29 | Univ Vanderbilt | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica |
| AU2011252974A1 (en) | 2010-05-12 | 2012-12-13 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CA2942687A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112020003292A2 (pt) | 2017-08-16 | 2020-08-18 | Vanderbilt University | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 |
-
2018
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt unknown
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11427573B2 (en) | 2022-08-30 |
| US20220259190A1 (en) | 2022-08-18 |
| US12291521B2 (en) | 2025-05-06 |
| IL272575B1 (en) | 2023-05-01 |
| WO2019036534A1 (en) | 2019-02-21 |
| JP7253832B2 (ja) | 2023-04-07 |
| EA202090467A1 (ru) | 2020-06-18 |
| EP3668865A1 (en) | 2020-06-24 |
| CN111225913B (zh) | 2024-05-31 |
| SG11202001264UA (en) | 2020-03-30 |
| AU2018317403B2 (en) | 2023-09-21 |
| IL272575A (en) | 2020-03-31 |
| CA3072493A1 (en) | 2019-02-21 |
| BR112020003292A2 (pt) | 2020-08-18 |
| AU2018317403A1 (en) | 2020-03-12 |
| IL272575B2 (en) | 2023-09-01 |
| KR102687118B1 (ko) | 2024-07-19 |
| CL2020000360A1 (es) | 2020-07-31 |
| JP2020531454A (ja) | 2020-11-05 |
| KR20200054204A (ko) | 2020-05-19 |
| ZA202001321B (en) | 2023-10-25 |
| US20200291019A1 (en) | 2020-09-17 |
| PE20200756A1 (es) | 2020-07-27 |
| CN111225913A (zh) | 2020-06-02 |
| US10508105B2 (en) | 2019-12-17 |
| UA128084C2 (uk) | 2024-04-03 |
| US20190055225A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020002576A2 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2019001553A1 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador. | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| MX2018009952A (es) | Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| MX2020013085A (es) | Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos. | |
| CO2017002494A2 (es) | N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| CR20160374A (es) | Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina | |
| MX386938B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| CL2019001329A1 (es) | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. |